SMMT · Summit Therapeutics Inc.
$13.11
+0.29 (+2.26%)
At close · Aug 19
Market Cap
$10.27B
Shares
797.75M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.11
Open$13.31
Day$12.92–13.39
52W close$12.55–26.98
Avg vol 30d4.2M
Short int36.2M · 4.5% float · 8.9d
Short vol53%
Last earningsJul 23, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 23
Up next
Next earnings call
Nov 12, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 23, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Very Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−21%
below
Price vs 50-day avg
−7%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−11%
trailing
6-month return
−17%
trailing
YTD return
−25%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $14 › 200d $17 — 200d above 50d
Institutional flow
Accumulating
+9% holders QoQ · +58 funds added
Insider flow
Accumulating
Net +$103.6M over 90 days · 0% sells
Short interest
Falling
4.54% of float · ▼ -2.9% MoM · 8.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
247 holders — near 3-yr high, broad support
Squeeze score
58
elevated · 0–100
Fundamentals
EPS growth
−365%
Y/Y
Free cash flow
$-323.6M
Balance sheet
$225.3M
net cash
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−21%
Bearish
Price vs 50-day avg
−7%
Bearish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
No cross
50d $14 › 200d $17 — 200d above 50d
Institutional flow
Accumulating
+9% holders QoQ · +58 funds added
Insider flow
Accumulating
Net +$103.6M over 90 days · 0% sells
Short interest
Falling
4.54% of float · ▼ -2.9% MoM · 8.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
247 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13
Now $13 · 4%
Range high $27
vs 200-day avg -21%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Basic and Diluted Weighted Average Shares Outstanding | 778.2M | Three Months Ended June 30, 2026 | — |
| Cash & Investments | $690.7M | as of June 30, 2026 | — |
| Non-GAAP G&A expenses non-GAAP | $18.2M | the second quarter of 2026 | — |
| Non-GAAP Net Loss Per Basic and Diluted Common Share non-GAAP | -$0.19 | second quarter of 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP Net Loss Per Basic and Diluted Common Share -$0.28
+$0.09 Stock-based compensation (Note 1)
= Non-GAAP Net loss Per Basic and Diluted Common Share -$0.19
|
|||
| Non-GAAP Operating Expenses non-GAAP | $151.8M | Three Months Ended June 30, 2026 | — |
| Non-GAAP R&D expenses non-GAAP | $133.6M | the second quarter of 2026 | — |
| patients treated in a commercial setting with ivonescimab in China | 70,000 | Q2 2026 | — |
| patients treated with ivonescimab in clinical studies globally | 4,000 | Q2 2026 | — |
| Total Ivonescimab Trials Sponsored by Summit, Akeso, or via Collaboration | 52 | as of July 16, 2026 | — |
| Total Trials Involving Ivonescimab on clinicaltrials.gov | 171 | as of July 16, 2026 | — |
| Aggregate cash and cash equivalents and short-term investments | $713.4M | December 31, 2025 | — |
| Non-GAAP net loss non-GAAP | $347.2M | full year 2025 | — |
GAAP → non-GAAP reconciliationGAAP GAAP Net Loss -1.08B
+732.4M Stock-based compensation (Note 1)
= Non-GAAP Net Loss -347.2M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SMMT
this stock
Summit Therapeutics Inc.
|
$10.27B | -25.0% | — | — | 4.5% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +24.0% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +21.8% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +8.9% | +20.8% | 20.3 | 3.3% |
|
ARGX
Argenx SE
|
$61.75B | +22.8% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SMMT | -13.2% | -11.1% | -17.0% | +0.7% | -25.0% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | -12.7% | -14.0% | -28.6% | -2.3% | -37.8% |
Key facts
CIK
1599298
CUSIP
86627T108
13F (30d)
230 filings
230 filers
Visit website
Investor relations